- Conditions
- HPV-Related Oropharynx Squamous Cell Carcinoma
- Interventions
- Radiation therapy, Cisplatin, Surgery
- Radiation · Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Fargo, North Dakota • Sioux Falls, South Dakota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma (OPSCC), Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma (SCC), Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer, Oropharyngeal Squamous Cell Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, HPV 16 Positive Oropharyngeal Tumors (OPC)
- Interventions
- Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease, Circulating Tumor DNA test (ctDNA test)
- Radiation · Diagnostic Test
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Columbia, Maryland • Glen Burnie, Maryland